Generation Bio
Generation Bio
GBIO
NASDAQ
0.50
USD
-1.96%
About
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES).
The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types.
Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 69.3K |
| Three Month Average Volume | 2.5M |
| High Low | |
| Fifty-Two Week High | 5.1 USD |
| Fifty-Two Week Low | 0.86 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 25 Oct 2023 |
| Price and Volume | |
| Current Price | 2.64 USD |
| Beta | 3 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.86% |
| Thirteen Week Relative Price Change | -22.43% |
| Twenty-Six Week Relative Price Change | -8.36% |
| Fifty-Two Week Relative Price Change | -55.92% |
| Year-to-Date Relative Price Change | 35.11% |
| Price Change | |
| One Day Price Change | -1.49% |
| Thirteen Week Price Change | -16.98% |
| Twenty-Six Week Price Change | 0.76% |
| Five Day Price Change | -0.38% |
| Fifty-Two Week Price Change | -44.77% |
| Year-to-Date Price Change | 60.00% |
| Month-to-Date Price Change | -20.96% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.06814 USD |
| Book Value Per Share (Most Recent Quarter) | 1.73017 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.06814 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.73017 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.61692 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.09156 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.19889 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.96348 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.3905 USD |
| Normalized (Last Fiscal Year) | -1.96348 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.96348 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.3905 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.96348 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.3905 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.99308 USD |
| Cash Per Share (Most Recent Quarter) | 3.25237 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.88186 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.31336 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.66413 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -6,863 |
| Cash Flow Revenue (Trailing Twelve Months) | -837 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,202.56% |
| Pretax Margin (Last Fiscal Year) | -2,144.51% |
| Pretax Margin (5 Year) | -8,879.44% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -2,346.93% |
| Operating Margin (Trailing Twelve Months) | -1,295.89% |
| Operating Margin (5 Year) | -9,184.65% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -2,144.51% |
| Net Profit Margin (Trailing Twelve Months) | -1,202.56% |
| Net Profit Margin (5 Year) | -8,879.44% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 19.06% |
| Tangible Book Value (5 Year) | 22.38% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 364.89% |
| Revenue Growth (3 Year) | 177.31% |
| Revenue Change (Trailing Twelve Months) | 1,397.05% |
| Revenue Per Share Growth | 171.21% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 19.61% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 35.10% |
| EPS Change (Trailing Twelve Months) | -14.76% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -216,942,000 |
| Net Debt (Last Fiscal Year) | -264,364,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 30 |
| Price to Sales (Trailing Twelve Months) | 13 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -60,142,000 |
| Free Cash Flow (Trailing Twelve Months) | -110,228,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -33.72% |
| Return on Assets (Trailing Twelve Months) | -47.28% |
| Return on Assets (5 Year) | -36.96% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -52.14% |
| Return on Equity (Trailing Twelve Months) | -85.71% |
| Return on Equity (5 Year) | -57.33% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -36.60% |
| Return on Investment (Trailing Twelve Months) | -51.64% |
| Return on Investment (5 Year) | -39.21% |